Literature DB >> 19488863

Proliferation inhibition effect of docetaxel combined with cisplatin on osteosarcoma cells.

Wei Jin1, Lin Cai, Guangfeng Niu, Hai Tao.   

Abstract

This research, studies the proliferation inhibition effect of combined use of docetaxel and cisplatin on osteosarcoma cells. The effects of docetaxel and cisplatin used alone and combined on osteosarcoma cell line HOS8603 were examined by means of cell count, morphologic observation, and flow cytometry (FCM). It was found that docetaxel and cisplatin either used alone or in combination, significantly inhibited the proliferation of osteosarcoma cells and apparently induced the apoptosis, and the effect of the combined drugs was better than that of the drugs used alone (growth inhibition ratio >or=59.34%, P < 0.05; apoptosis ratio = 18.31%, P < 0.01). Therefore, the combined use of docetaxel and cisplatin is more effective than either of the drugs used alone in inhibiting the proliferation of osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19488863     DOI: 10.1007/s12032-009-9240-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  15 in total

Review 1.  [Chemotherapy of prostate cancer: potential role of docetaxel].

Authors:  S Bracarda
Journal:  Tumori       Date:  2001 Nov-Dec       Impact factor: 2.098

Review 2.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

3.  Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.

Authors:  D R Gandara; E Vokes; M Green; P Bonomi; R Devore; R Comis; D Carbone; D Karp; C Belani
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

Authors:  M C Bissery; D Guénard; F Guéritte-Voegelein; F Lavelle
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

5.  Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

Authors:  A D Roth; R Maibach; G Martinelli; N Fazio; M S Aapro; O Pagani; R Morant; M M Borner; R Herrmann; H Honegger; F Cavalli; P Alberto; M Castiglione; A Goldhirsch
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

Review 6.  Docetaxel in ovarian cancer.

Authors:  Pedro F Escobar; Peter G Rose
Journal:  Expert Opin Pharmacother       Date:  2005-12       Impact factor: 3.889

7.  Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer.

Authors:  Orlando Guntinas-Lichius; Stefan Appenrodt; Florian Veelken; Barbara Krug
Journal:  Laryngoscope       Date:  2006-04       Impact factor: 3.325

8.  An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.

Authors:  Michelle B Mintz; Rebecca Sowers; Kevin M Brown; Sara C Hilmer; BethAnne Mazza; Andrew G Huvos; Paul A Meyers; Bonnie Lafleur; Wendy S McDonough; Michael M Henry; Keri E Ramsey; Cristina R Antonescu; Wen Chen; John H Healey; Aaron Daluski; Michael E Berens; Tobey J Macdonald; Richard Gorlick; Dietrich A Stephan
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

9.  Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.

Authors:  Shuichi Hironaka; Sadamoto Zenda; Narikazu Boku; Akira Fukutomi; Takayuki Yoshino; Yusuke Onozawa
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

10.  Optimal combination chemotherapy and chemoradiotherapy with etoposide for advanced cervical squamous cancer cells in vitro.

Authors:  Tetsuji Tanaka; Tao Bai; Kazunori Yukawa; Naohiko Umesaki
Journal:  Oncol Rep       Date:  2006-04       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.